A quick finger prick and a few drops of blood on a card that can be sent in regular mail—This approach could soon make Alzheimer's testing much more accessible worldwide. A European study led by ...
Needham downgraded Biogen Inc (NASDAQ:BIIB), citing limited catalysts for the company over the next year. Alzheimer’s drug ...
Worldcrunch on MSN15h
Leqembi, Is This New Drug The Turning Point In Curing Alzheimer’s?That Thursday, for the first time, the European Medicines Agency (EMA) approved a drug that targets the cause — not just the ...
Our Director of Research Dr Sheona Scales describes her four highlights from this year's Clinical Trials on Alzheimer's ...
Lecanemab, a drug designed to slow the progression of early stage Alzheimer's will not be available to patients in Sweden for ...
Viral Chatter on MSN18h
Scientists Link Early Neuron Loss to Alzheimer’s TreatmentsA landmark study examining over 3.4 million brain cells has revealed that Alzheimer’s disease progresses through two distinct ...
Alzheimer’s trials face the unique challenge of studying participants with cognitive decline, amid a move towards digital ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback